JNJ Hits 52-Week High, Impresses with Q4 Results and Guidance

# Johnson & Johnson (JNJ) Stock Analysis: Hitting 52-Week Highs with Mixed Analyst Outlooks In this episode, we dive into Johnson & Johnson's impressive stock performance as JNJ reaches new 52-week highs around $240 per share. We explore the company's strong Q4 earnings report showing 9.1% revenue growth, analyze its attractive 2.2% dividend yield, and break down the varied analyst perspectives—from Morgan Stanley's bullish $262 target to long-term forecasts predicting potential growth to $288 by 2028. Discover why healthcare giant JNJ continues to demonstrate resilience despite ongoing litigation concerns, and what this means for investors considering this blue-chip stock in their portfolios. Keywords: Johnson & Johnson stock, JNJ analysis, healthcare stocks, dividend investing, pharmaceutical stocks, blue-chip investments, stock market analysis, analyst ratings, 52-week high stocks For more http://www.quietplease.ai Stock up on these deals https://amzn.to/3QFpYIX This content was created in partnership and with the help of Artificial Intelligence AI.